NCT07192081View on ClinicalTrials.gov

Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy

NARecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

January 4, 2026

Study Completion Date

February 28, 2026

Conditions
IntubationAnesthesiaLaparoscopic CholecystectomyHemodynamic Response to Laryngoscopy
Interventions
DRUG

Labetalol

Labetalol 0.25 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.

DRUG

Lignocaine

Lignocaine 1.5 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.

Trial Locations (1)

25000

RECRUITING

Hayatabad Med Complex, Peshawar

All Listed Sponsors
collaborator

Hayatabad Medical Complex

OTHER_GOV

lead

Dr. Waseem Ullah

OTHER_GOV

NCT07192081 - Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy | Biotech Hunter | Biotech Hunter